Suspended

Comparison of Trabeculectomy and Argon Laser Trabeculoplasty Sequences in Advanced Glaucoma Management

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Eye Diseases

+ Glaucoma

+ Ocular Hypertension

From 35 to 80 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: April 1988
See protocol details

Summary

Principal SponsorNational Eye Institute (NEI)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 1988

Actual date on which the first participant was enrolled.

The Advanced Glaucoma Intervention Study (AGIS) focuses on managing advanced glaucoma, a condition where medication alone can't lower eye pressure adequately, causing vision loss. Before 1980, a surgical procedure called trabeculectomy was commonly used. However, laser trabeculoplasty has gained popularity since then. The study aims to understand which sequence of these interventions yields the best long-term results, as success varies and some patients may need multiple procedures over time. The study involves individuals with advanced glaucoma, comparing two intervention sequences to manage the disease. Participants are randomly assigned to one of two sequences: either starting with trabeculectomy, followed by argon laser trabeculoplasty (ALT) if the first procedure fails, then a second trabeculectomy if ALT fails; or starting with ALT, followed by trabeculectomy if ALT fails, then another trabeculectomy if the first one fails. These interventions are supplemented with medication as needed. The study follows all patients for at least 5 years, scheduling regular examinations to evaluate visual function loss, intervention failure rates, complication rates, and the need for additional therapy. The primary outcome is the percentage of eyes with decreased vision, while secondary outcomes include sustained vision loss, intervention failures, number of prescribed glaucoma medications, and eye pressure levels.

Official TitleAdvanced Glaucoma Intervention Study (AGIS)
Principal SponsorNational Eye Institute (NEI)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 35 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesGlaucomaOcular Hypertension

Criteria

Men and women between the ages of 35 and 80 with open-angle glaucoma that was not successfully controlled by medication were eligible for enrollment.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 13 locations

Suspended

Yale University School of Medicine, Yale Eye Center

New Haven, United StatesOpen Yale University School of Medicine, Yale Eye Center in Google Maps
Suspended

Georgetown University, University Ophthalmic Consultants of Washington, Eye Associates of Washington, D.C.

Washington D.C., United States
Suspended

Emory University, Emory Eye Center

Atlanta, United States
Suspended

Piedmont Hospital, Eye Consultants of Atlanta

Atlanta, United States
Suspended13 Study Centers